Table 3 Summary of efficacy after PSM in cohort 1 (Apatinib-based vs. Chemotherapy-based)

All comers, n

30

30

-

-

Objective response, n (%; 95% CI)

15 (50.0; 31.3–68.7)

2 (6.7; 0.8–22.1)

< 0.001

Disease control, n (%; 95% CI)

27 (90.0; 73.5–97.9)

6 (20; 7.7–38.6)

< 0.001

Progression-free survival, month (95% CI)

7.8 (6.5–12.8)

2.2 (2.0-3.3)

0.21 (0.11–0.39)

< 0.001

Overall survival, month (95% CI)

20.3 (15.5-NR)

9.0 (5.3–13.3)

0.20 (0.09–0.44)

< 0.001

1st line, n

8

8

-

-

Objective response, n (%; 95% CI)

7 (87.5; 47.3–99.7))

1 (12.5; 0.3–52.7)

-

0.010

Disease control, n (%; 95% CI)

8 (100.0)

2 (25.0; 3.2–65.1)

-

0.007

2^nd+line, n

22

22

-

-

Objective response, n (%; 95% CI)

8 (36.4; 17.2–59.3)

1 (4.5; 0.1–22.8)

-

0.025

Disease control, n (%; 95% CI)

18 (81.8; 59.7–94.8)

4 (18.2; 5.2–40.3)

-

< 0.001